A Multicentre Study of Patient Survival, Disability, Quality of Life and Cost of Care

Abstract

This is the first study to present a comprehensive comparison of direct costs, DD and HR-QOL of patients with AIDS between two time periods. The use of a case-control design has enabled changes in costs and outcomes to be linked to the introduction of HAART in Italy in 1997.

The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution

“…As efforts to improve access to HIV treatment in resource-limited areas such as sub-Saharan Africa increase [5], strategies to manage the adverse effects of BFR on QoL become more crucial, as these management strategies may enhance treatment adherence [6]. Measures of QoL provide valuable information about patients' well being, psychological and social functioning, and the cost-effectiveness of intervention trials [7]. Therefore, there is a need to test and identify effective interventions that may alleviate the psychological and social consequences of HAART-and HIV-related BFR and enhance QoL of HIV+ patients receiving HAART.…”

The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care

“…[1][2][3][4] The proportion of medical costs attributable to antiretroviral therapy in our study (61%) was also similar to that found in previous studies. [1,4,8] The association of baseline CD4+ cell count with cost of medical care has been previously demonstrated. [1] Age as a factor associated with increased total medical costs is not surprising as it likely acted as a surrogate for increased co-morbid illness.…”

“…[5] After the introduction of potent combination antiretroviral therapy, the need for hospitalization and the incidence of opportunistic illness decreased considerably. [6][7][8] It is now estimated that 54−64% of healthcare expenditures in HIV-infected populations in resourcerich settings are attributed to the cost of combination antiretroviral therapy. [1,4,8] Despite the expense, antiretroviral therapy is cost effective for HIV-infected individuals in resource-rich (and resource-limited) settings.…”

“…[6][7][8] It is now estimated that 54−64% of healthcare expenditures in HIV-infected populations in resourcerich settings are attributed to the cost of combination antiretroviral therapy. [1,4,8] Despite the expense, antiretroviral therapy is cost effective for HIV-infected individuals in resource-rich (and resource-limited) settings. [9][10][11][12][13] Excellent adherence to antiretroviral therapy increases the likelihood of successful clinical outcomes and would thus be expected to decrease non-antiretroviral healthcare costs.…”

Economic evaluation of HIV treatments: The I.CO.N.A. cohort study

“…In a recent study that retrospectively compared data of a cohort of symptomatic patients in 1994 with a similar cohort in 1998, a reduction of 3925 euro (1999 prices) in direct health costs per person-year was calculated. In 1998, ART costs per patient-year were equal to 7283 euro and accounted for 63.5% of total direct medical costs [20].…”